Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis
Pharmaceuticals · 26.02.2026 · 19 (3) · 365
DOI: 10.3390/ph19030365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.02.2026. Verfasst von Ali Hindi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Glucagon-like peptide-1 receptor agonists are increasingly prescribed for weight loss, but concerns remain regarding adverse events beyond gastrointestinal, renal, and pancreatic effects. Understanding these risks is essential to guide safe clinical application and public health policy. The study aims to characterize psychiatric risks, administration-related adverse events, and patterns of inappropriate use associated with semaglutide, liraglutide, and tirzepatide for weight management.
Methods
Disproportionality analysis using proportional reporting ratios and reporting odds ratios was conducted to detect significant signals in adverse event reports within the U.S. Food and Drug Administration Adverse Event Reporting System, identifying semaglutide, liraglutide, or tirzepatide as drugs used for weight loss while excluding gastrointestinal, renal, and pancreatic adverse events.
Results
Among 40,253 adverse event reports (68.6% female; median ages: semaglutide, 62 years; liraglutide, 59 years; tirzepatide, 53 years), semaglutide demonstrated the strongest disproportionality signal for psychiatric adverse events, notably anxiety (PRR 1.34, 95% CI 1.18–1.51), depression (PRR 1.83, 95% CI 1.62–2.07), and suicidal ideation (PRR 3.44, 95% CI 2.98–3.97). Tirzepatide showed markedly higher signals for injection-site reactions (PRR 7.98, 95% CI 7.8–8.18) and inappropriate use, including incorrect dosing and off-label administration (PRR 5.98, 95% CI 5.9–6.06).
Conclusions
In real-world use, semaglutide is disproportionately associated with psychiatric adverse events, whereas tirzepatide demonstrates higher rates of injection-site complications and misuse. Liraglutide presents a comparatively lower risk profile. These findings underscore the need for vigilant psychiatric monitoring, patient education on injection technique and dosing, and stronger regulatory oversight to reduce misuse of GLP-1 receptor agonists for weight loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.
- Clinical Pharmacy Department, Alexandria Police Hospital, Alexandria 21511, Egypt.
ORCID-Profile: Ali Hindi, Mohamed Mekkawy, Hala Shokr
Zitieren
APA
Hindi, A., Mekkawy, M., & Shokr, H. (2026). Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. Pharmaceuticals, 19(3), 365. https://doi.org/10.3390/ph19030365
Vancouver
Hindi A, Mekkawy M, Shokr H. Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. Pharmaceuticals. 2026;19(3):365. doi:10.3390/ph19030365
BibTeX
@article{Hindi2026,
author = {Hindi, Ali and Mekkawy, Mohamed and Shokr, Hala},
title = {Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {3},
pages = {365},
doi = {10.3390/ph19030365}
}
EUVIMED